[go: up one dir, main page]

LT3157531T - Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti - Google Patents

Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti

Info

Publication number
LT3157531T
LT3157531T LTEP15811714.3T LT15811714T LT3157531T LT 3157531 T LT3157531 T LT 3157531T LT 15811714 T LT15811714 T LT 15811714T LT 3157531 T LT3157531 T LT 3157531T
Authority
LT
Lithuania
Prior art keywords
stimulation
compositions
treatment
conditions
methods
Prior art date
Application number
LTEP15811714.3T
Other languages
English (en)
Inventor
Michael Zasloff
Original Assignee
Enterin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin, Inc. filed Critical Enterin, Inc.
Publication of LT3157531T publication Critical patent/LT3157531T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
LTEP15811714.3T 2014-06-23 2015-06-22 Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti LT3157531T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Publications (1)

Publication Number Publication Date
LT3157531T true LT3157531T (lt) 2021-07-12

Family

ID=54869043

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15811714.3T LT3157531T (lt) 2014-06-23 2015-06-22 Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti

Country Status (19)

Country Link
US (10) US10040817B2 (lt)
EP (1) EP3157531B1 (lt)
JP (2) JP6692300B2 (lt)
CN (2) CN106535902B (lt)
BR (1) BR112016029917A2 (lt)
CA (1) CA2951720C (lt)
CY (1) CY1124554T1 (lt)
DK (1) DK3157531T3 (lt)
ES (1) ES2878077T3 (lt)
HR (1) HRP20211005T1 (lt)
HU (1) HUE054828T2 (lt)
LT (1) LT3157531T (lt)
MX (2) MX2016017368A (lt)
PL (1) PL3157531T3 (lt)
PT (1) PT3157531T (lt)
RS (1) RS62064B1 (lt)
SI (1) SI3157531T1 (lt)
SM (1) SMT202100373T1 (lt)
WO (1) WO2015200195A1 (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
US20180344748A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating chronic inflammatory diseases
MA50094A (fr) * 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
WO2019089365A1 (en) * 2017-10-30 2019-05-09 Enterin Laboratories, Inc. New squalamine solid forms and methods of making the same
CN112312917A (zh) * 2018-03-27 2021-02-02 因特尔公司 用于治疗幻觉及其相关病症的方法和组合物
US20190381071A1 (en) * 2018-06-13 2019-12-19 Enterin, Inc. Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
US20210260078A1 (en) * 2018-08-03 2021-08-26 Philadelphia Low dosage intranasal aminosterol dosage forms and methods of using the same
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATING GUT-BRAIN AXIS DISORDERS
WO2021025988A1 (en) * 2019-08-02 2021-02-11 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
JP3546886B2 (ja) 1993-03-10 2004-07-28 ジェネーラ コーポレーション ステロイド誘導体、それらを含む薬剤組成物、及び抗生物質又は消毒薬としてのそれらの使用
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
AU3512595A (en) 1994-09-13 1996-03-29 Magainin Pharmaceuticals, Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
JP4104164B2 (ja) * 1995-06-07 2008-06-18 ジェネーラ コーポレーション ナトリウム／プロトン交換体（ｎｈｅ）の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のｎｈｅ阻害効果を評価する方法
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6147060A (en) 1996-04-26 2000-11-14 Magainin Pharmaceuticals Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
AU726909B2 (en) 1996-05-17 2000-11-23 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
WO1998019682A1 (en) 1996-11-01 1998-05-14 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and uses therefor
EP1105407B1 (en) 1998-08-12 2007-10-10 Genaera Corporation Aminosterol compounds and uses thereof
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1358200A4 (en) * 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACID TO IMPROVE THE ORAL ABSORPTION AND SYSTEMIC BIOVERABILITY OF MEDICAMENTS
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2006116309A2 (en) 2005-04-25 2006-11-02 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
CA2922021C (en) 2007-09-06 2018-01-09 Ohr Pharmaceutical, Inc. A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
HUE044769T2 (hu) 2012-04-20 2019-11-28 Ohr Pharmaceutical Inc Aminoszteroidok PTP1B-vel összefüggõ betegségek kezelésére
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
US9504700B2 (en) 2012-12-20 2016-11-29 Mount Desert Island Biological Laboratory Methods and compositions for stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
JP6692300B2 (ja) 2020-05-13
PL3157531T3 (pl) 2021-11-15
CN113559108A (zh) 2021-10-29
CN106535902A (zh) 2017-03-22
HRP20211005T1 (hr) 2021-09-17
US20180319837A1 (en) 2018-11-08
US10633413B2 (en) 2020-04-28
MX2021005489A (es) 2021-06-18
CA2951720C (en) 2023-09-26
EP3157531A4 (en) 2018-05-16
EP3157531A1 (en) 2017-04-26
MX2016017368A (es) 2017-08-24
CN106535902B (zh) 2021-05-25
US20150368290A1 (en) 2015-12-24
CA2951720A1 (en) 2015-12-30
US20190194243A1 (en) 2019-06-27
CY1124554T1 (el) 2022-07-22
JP7010979B2 (ja) 2022-02-10
US10975116B2 (en) 2021-04-13
US20170327530A1 (en) 2017-11-16
JP2017519775A (ja) 2017-07-20
US10196420B2 (en) 2019-02-05
US11440936B2 (en) 2022-09-13
DK3157531T3 (da) 2021-07-05
RS62064B1 (sr) 2021-07-30
US20190194244A1 (en) 2019-06-27
US10208080B2 (en) 2019-02-19
US20190185513A1 (en) 2019-06-20
US10040817B2 (en) 2018-08-07
US20220220148A1 (en) 2022-07-14
HUE054828T2 (hu) 2021-10-28
EP3157531B1 (en) 2021-03-31
US20180002370A1 (en) 2018-01-04
JP2020097587A (ja) 2020-06-25
WO2015200195A1 (en) 2015-12-30
ES2878077T3 (es) 2021-11-18
US20170326156A1 (en) 2017-11-16
SMT202100373T1 (it) 2021-07-12
BR112016029917A2 (pt) 2017-08-22
US20180327445A1 (en) 2018-11-15
SI3157531T1 (sl) 2021-09-30
US10208079B2 (en) 2019-02-19
PT3157531T (pt) 2021-07-01

Similar Documents

Publication Publication Date Title
LT3157531T (lt) Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
EP3212233A4 (en) Combination therapy for treatment of disease
EP3263132C0 (en) Composition for treating il-6-related diseases
HK1251482A1 (zh) 用於治療補體介導的疾病的組合物和方法
HUE058713T2 (hu) Kinolin-származékok gyulladásos megbetegedések kezelésére
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
HK1258994A1 (zh) 用於疾病治療的方法
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
PL3348273T3 (pl) Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych
LT3153511T (lt) 2-acilaminotiazolo dariniai, skirti panaudoti šlapimo pūslės/šlapimo takų ligų prevencijai arba gydymui
IL252779A0 (en) Prevention and treatment of inflammatory conditions
GB201515244D0 (en) Treatment of inflammatory disease or condition
IL259381B (en) Miravegron for the treatment of retinal diseases
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
RS63859B1 (sr) N,n-bis-2-merkaptoetil izoftalamid za lečenje neurodegenerativnih bolesti
GB201500555D0 (en) Method and device for the treatment of diseases
EP3223828A4 (en) Methods for the treatment and prevention of asbestos-related diseases